You are currently viewing a new version of our website. To view the old version click .
Cancers
  • Correction
  • Open Access

24 October 2023

Correction: Ding et al. MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial–Mesenchymal Transition (EMT) Pathways. Cancers 2023, 15, 3185

,
,
,
,
and
1
Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212000, China
2
Hematological Disease Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212001, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
This article belongs to the Section Cancer Biomarkers
In the published paper [1], there was an error regarding the affiliation for Huizhi Wang. Yuntao Ding and Huizhi Wang contributed equally to this work and share co-first authorship, as stated in the Author Contributions section. The updated affiliation should include: †—These authors contributed equally to this work. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Ding, Y.; Wang, H.; Liu, J.; Jiang, H.; Gong, A.; Xu, M. MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial-Mesenchymal Transition (EMT) Pathways. Cancers 2023, 15, 3185. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.